Evidence map›Paper›PMID 41135412›Full record

ReviewThe Journal of pharmacology and experimental therapeutics2025

Chemokine-chemokine receptor networks in conventional type I dendritic cells: an opportunity to prime and boost anticancer immunity.

Ning Kuo, Cheyanne Kristen Shinn, Shiruyeh Schokrpur, Juliana Idoyaga, Tracy Handel, Jorge Silvio Gutkind

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ning KuoDepartment of Biomedical Sciences, School of Medicine, University of California, San Diego, La Jolla, California; Moores Cancer Center, University of California San Diego, La Jolla, California; Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, California. Electronic address: n3kuo@ucsd.edu.
Cheyanne Kristen ShinnMoores Cancer Center, University of California San Diego, La Jolla, California; Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, California.
Shiruyeh SchokrpurDivision of Hematology/Oncology, Department of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, California.
Juliana IdoyagaDepartment of Biomedical Sciences, School of Medicine, University of California, San Diego, La Jolla, California; Moores Cancer Center, University of California San Diego, La Jolla, California; Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, California; Department of Molecular Biology, School of Biological Sciences, University of California San Diego, La Jolla, California.
Tracy HandelMoores Cancer Center, University of California San Diego, La Jolla, California; Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, California.
Jorge Silvio GutkindMoores Cancer Center, University of California San Diego, La Jolla, California; Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, California. Electronic address: sgutkind@health.ucsd.edu.

Funding

Targeting Signaling Vulnerabilities for Oral Cancer PreventionR01DE026644 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jorge Silvio Gutkind, SCOTT M LIPPMAN · 2017 to 2026
$4.7M
Mapping immuno-genomic drivers of the head and neck precancer invasive-disease transitionU01CA290479 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ludmil B Alexandrov, Jorge Silvio Gutkind · 2023 to 2026
$3.1M
Reprogramming the Tumor Immune Microenvironment with Chemokines to Potentiate Immune Oncology Treatments in Oral CancerR01DE033909 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jorge Silvio Gutkind, Tracy M Handel · 2024 to 2026
$1.8M
Cellular and Molecular Pharmacology Training ProgramT32GM153123 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JOAN HELLER BROWN, Tracy M Handel · 2024 to 2026
$1.3M
NCI NIH HHS U01 CA290479NIDCR NIH HHS R01 DE026644NIDCR NIH HHS R01 DE033909NIGMS NIH HHS T32 GM153123
6 · The paper itself

Abstract

Type I conventional dendritic cells (cDC1s) are key drivers of antitumor immunity. In human cancers, their presence correlates with better prognosis and survival benefits. In preclinical mouse tumor models, cDC1s are indispensable for successful T-cell-mediated tumor killing and therapeutic response to immune checkpoint blockade therapies. The essential role of cDC1s in antitumor immunity stems from their ability to uptake tumor-derived antigens and traffic them to the tumor-draining lymph node (tdLN) for T-cell priming. At the tdLN, cDC1s present tumor antigens to naïve CD8

Indexed as

ChemokinesDendritic CellsNeoplasmsReceptors, ChemokineAnimalsHumansImmunotherapyChemokinesReceptors, ChemokineCancerCancer immunologyChemokinesDendritic cellsImmunologyImmunotherapy

Identifiers

PMID41135412
PMCPMC12919738

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.